Anticoagulant

Patient-relevant bleeding negatively affected quality of life and treatment adherence among patients on anticoagulant therapy, according to results of a survey presented at International Society on Thrombosis and Hemostasis Congress.

Assessing initial experiences in Japan and age-related clinical outcomes in patients with nonvalvular atrial fibrillation undergoing percutaneous left atrial appendage closure.

Revisiting reasons for patient refusal or physician choice not to prescribe oral anticoagulation could improve use of anticoagulants in patients with atrial fibrillation at increased risk, researchers reported.

Determining the safety of enoxaparin and apixaban (Eliquis, Bristol Myers Squibb/Pfizer) in patients hospitalized but not intubated with confirmed COVID-19.

Anticoagulant use for at least 4 weeks after transcatheter mitral valve repair reduced risk for stroke without increasing the rates of bleeding compared with no anticoagulants, data from a meta-analysis show.

Techdow USA announced the FDA approval of its generic enoxaparin sodium for marketing in the U.S.

NEW ORLEANS — A therapeutic vs. prophylactic dose of anticoagulation therapy did not significantly improve outcomes for noncritically ill patients hospitalized with COVID-19, though fewer therapeutic dose-treated patients died at 30 days.

Efficacy of conventional catheter-directed thrombolysis plus anticoagulation vs. anticoagulation monotherapy in acute intermediate-high-risk PE.

The FDA granted fast track designation for Tecarfarin, a novel cardiorenal therapy by Cadrenal Therapeutics, to prevent systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation.

Patients with venous thromboembolism treated with anticoagulants for more than 3 months had a lower risk for major adverse cardiovascular events, according to a study published in CHEST.